<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657043</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTV-002</org_study_id>
    <nct_id>NCT03657043</nct_id>
  </id_info>
  <brief_title>A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)</brief_title>
  <official_title>Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study tisotumab vedotin to find out what its side effects are and to see if
      it works for platinum-resistant ovarian cancer (PROC). It will test different doses of
      tisotumab vedotin that are given at different times. It will also compare the side effects
      and ability to treat tumors of these different doses and schedules. In this study, there will
      be a safety run-in group of approximately 12 patients that will look at a dose-dense
      treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In
      addition to the safety run-in patients, there will be three groups in the study. One group
      will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get
      tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of
      tisotumab vedotin (TV) administered every 3 weeks or on Days 1, 8, and 15 of every 4-week
      cycle (dose-dense regimen; 3Q4W) for patients with epithelial ovarian cancer, primary
      peritoneal cancer, or fallopian tube cancer that has relapsed within 6 months of the
      completion of platinum-based treatment and determined to be platinum resistant. All patients
      must have PROC and be eligible for single agent chemotherapy.

      The safety run-in period will evaluate the safety of a weekly schedule. The highest dose
      level that is considered safe will be the recommended phase 2 dose (RP2D) and will be used in
      Part A. In Part A, participants will be randomized in a 1:1 ratio to receive tisotumab
      vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1,
      8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified.
      Participants who enroll in Part B will receive tisotumab vedotin on Days 1, 8, and 15 of
      every 4-week cycle (weekly regimen) at a pre-specified dose level, if the dose level is
      considered safe and tolerable in the safety run-in period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) (Safety Run-in only)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed objective response rate (ORR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events that are Grade 3+, treatment-related, or serious (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed and unconfirmed ORR (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Antigen 125 (CA-125) response rate according to Gynecologic Cancer Intergroup (GCIG) criteria (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients who have at least a 50% reduction in CA-125 value from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response according to the Gynecological Cancer Intergroup (GCIG) combined RECIST and CA-125 criteria (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients with complete response (CR), partial response (PR), or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the start of study treatment to the first documentation of objective response (CR or PR that is subsequently confirmed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the start of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter: Cmax (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUClast (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies (ATA) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Run-In (Dose-dense Schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28-day, 3 dose cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Tisotumab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21-day, single dose cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Tisotumab Vedotin (Dose-dense Schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28-day, 3 dose cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Tisotumab Vedotin (Dose-dense Schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28-day, 3 dose cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tisotumab vedotin</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Part A: Tisotumab Vedotin</arm_group_label>
    <arm_group_label>Part A: Tisotumab Vedotin (Dose-dense Schedule)</arm_group_label>
    <arm_group_label>Part B: Tisotumab Vedotin (Dose-dense Schedule)</arm_group_label>
    <arm_group_label>Safety Run-In (Dose-dense Schedule)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or
             fallopian tube cancer

          -  Safety run-in only: PROC. Patients may have received more than 1 prior systemic
             treatment regimen in the PROC setting.

          -  Part A and Part B only: Patients with PROC who have received at most 1 prior cytotoxic
             chemotherapy regimen in the PROC setting

          -  Measurable disease according to RECIST v1.1 as assessed by the investigator

          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

          -  Life expectancy of at least 3 months

          -  Able to provide fresh or archival tissue for biomarker analysis

        Exclusion Criteria:

          -  Primary platinum-refractory disease, defined as disease progression within 2 months of
             completion of first line platinum-based therapy

          -  Patients with clinical symptoms or signs of gastrointestinal obstruction with the past
             6 months or who currently require parenteral nutrition

          -  Hematological: Known past or current coagulation defects leading to an increased risk
             of bleeding, diffuse alveolar hemorrhage from vasculitis, known bleeding diathesis,
             ongoing major bleeding, or trauma with increased risk of life-threatening bleeding
             within 8 weeks of trial entry

          -  Cardiovascular: Clinically significant cardiac disease including uncontrolled
             hypertension, unstable angina, acute myocardial infarction with 6 months of screening,
             serious cardiac arrhythmia requiring medication, medical history of congestive heart
             failure, or medical history of decreased cardiac ejection fraction of &lt;45%

          -  Ophthalmological: Active ocular surface disease at baseline or prior episode of
             cicatricial conjunctivitis or Stevens Johnson syndrome

          -  Prior treatment with MMAE-derived drugs

          -  Inflammatory bowel disease including Crohn's disease and ulcerative colitis

          -  Ongoing, acute, or chronic inflammatory skin disease

          -  Uncontrolled tumor-related pain

          -  Inflammatory lung disease requiring chronic medical therapy

          -  Grade 3 or higher pulmonary disease unrelated to underlying malignancy

          -  Uncontrolled pleural or pericardial effusions

          -  Grade &gt;1 peripheral neuropathy

          -  Patients who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo Nicacio, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>8663337436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Cancer Center South Bay</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hann</last_name>
      <phone>408-426-4900</phone>
      <email>bhann@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Omid Tehrani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Health System (PVHS)</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Wood</last_name>
      <phone>970-297-6163</phone>
      <email>jill.wood2@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Moya</last_name>
      <phone>786-596-2000</phone>
      <email>IsabelMoy@BaptistHealth.net</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Garcia</last_name>
      <phone>786-596-2000</phone>
      <email>GiovanniG@BaptistHealth.net</email>
    </contact_backup>
    <investigator>
      <last_name>John Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Rokakis</last_name>
      <phone>813-745-4673</phone>
      <email>Eleni.rokakis@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hye Sook Chon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Wheatley</last_name>
      <phone>800-736-2273</phone>
      <email>dwheatley@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Sharad Ghamande</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dewi Mouzoukos</last_name>
      <phone>913-588-6029</phone>
      <email>dmouzoukos@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tennery Carttar</last_name>
      <phone>913-588-6029</phone>
      <email>tcarttar@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Jewell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Wolgast</last_name>
      <phone>313-576-8711</phone>
      <email>wolgasta@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Robert Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri Healthcare / Ellis Fischel Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherezad Mistry</last_name>
      <phone>573-884-7482</phone>
      <email>MistryS@health.missouri.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Tuller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Blair</last_name>
      <phone>551-996-5809</phone>
      <email>Danielle.Blair@hackensackmeridian.org</email>
    </contact>
    <contact_backup>
      <last_name>Lori Cappello</last_name>
      <phone>201-996-5900</phone>
      <email>lori.cappello@hackensackmeridian.org</email>
    </contact_backup>
    <investigator>
      <last_name>Donna McNamara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Chelsea</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Ruiz</last_name>
      <phone>212-367-1863</phone>
      <email>meghan.ruiz@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Stephanie Blank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Kracikova</last_name>
      <email>martina.kracikova@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Blank</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Vattakalam</last_name>
      <phone>212-326-5720</phone>
      <email>rmv2110@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>June Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Carter</last_name>
      <phone>919-668-1070</phone>
      <email>Meredith.carter@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Angeles Secord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Smrekar</last_name>
      <phone>216-445-9451</phone>
      <email>masmre@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Haider Mahdi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, The</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Previte</last_name>
      <phone>216-445-9451</phone>
      <email>previtn@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Haider Mahdi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Clinical Trials Management Office</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Hwang</last_name>
      <phone>614-247-7793</phone>
      <email>Sarah.Hwang@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David O'Malley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reitha Phillips</last_name>
      <phone>216-445-9451</phone>
      <email>phillir2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Haider Mahdi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center / Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Bane</last_name>
      <phone>214-820-7537</phone>
      <email>mark.bane@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Carlos Becerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Mouton</last_name>
      <phone>713-703-2398</phone>
      <email>Alice.mouton@renovatioclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mary Crow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6271</phone>
      <email>AM7BD@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Duska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Alfonso Cortes Salgado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Gonzalez Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum-resistant</keyword>
  <keyword>Antibody drug conjugate</keyword>
  <keyword>Tisotumab vedotin</keyword>
  <keyword>PROC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

